Al-Suliman Walaa, Wehbeh Issa, Al-Hafyan Salim
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Damascus University, Damascus, Syrian Arab Republic.
Department of Pharmacy, Arab Private University for Science, Hama, Syrian Arab Republic.
BMC Oral Health. 2025 Sep 1;25(1):1393. doi: 10.1186/s12903-025-06777-7.
Bleeding after tooth extraction is a significant challenge, particularly in patients taking anticoagulants such as aspirin and warfarin, as the use of these medications increases the risk of prolonged bleeding. This study aimed to evaluate the effectiveness of the hemostatic agents, Surgicel and Gelfoam, in controlling bleeding and improving healing after extraction in this patient group.
A clinical study was conducted on 40 patients, divided into two groups based on the type of anticoagulant used (aspirin or warfarin). Each patient received treatment with different hemostatic dressings: Gelfoam was applied to one side and Surgicel to the other. Bleeding was assessed using the VIBe scale, and the rate of gingival healing was measured using the Gingival Healing Index (GHI) on days three (D3) and seven (D7). Pain was also assessed using the Visual Analogue Scale (VAS), and late bleeding rates were analyzed 24 h after extraction.
The results showed that Surgicel was more effective than Gelfoam in achieving hemostasis and reducing delayed bleeding (p < 0.05). Patients using Surgicel also reported faster improvement in tissue healing compared to patients using Gelfoam, particularly on day 7 after extraction. Additionally, pain scores were significantly lower in patients treated with Surgicel compared to Gelfoam, reflecting its role in improving patient comfort and accelerating healing.
This study supports the use of Surgicel as a more effective option for controlling bleeding and promoting tissue healing in patients taking anticoagulants, reducing the need for treatment adjustments that may increase the risk of thrombosis. The study recommends further studies to evaluate the long-term benefits of using different hemostatic agents in this patient population.
The trial was retrospectively registered at the ISRCTN registry (ISRCTN19155058) on 29 May 2025.
拔牙后出血是一个重大挑战,尤其对于服用阿司匹林和华法林等抗凝剂的患者,因为使用这些药物会增加出血时间延长的风险。本研究旨在评估止血剂速即纱(Surgicel)和明胶海绵(Gelfoam)在该患者群体拔牙后控制出血和促进愈合方面的有效性。
对40例患者进行了一项临床研究,根据所使用的抗凝剂类型(阿司匹林或华法林)分为两组。每位患者接受不同的止血敷料治疗:一侧应用明胶海绵,另一侧应用速即纱。使用VIBe量表评估出血情况,并在第3天(D3)和第7天(D7)使用牙龈愈合指数(GHI)测量牙龈愈合率。还使用视觉模拟量表(VAS)评估疼痛情况,并在拔牙后24小时分析迟发性出血率。
结果表明,在实现止血和减少延迟出血方面,速即纱比明胶海绵更有效(p < 0.05)。与使用明胶海绵的患者相比,使用速即纱的患者在组织愈合方面也报告了更快的改善,尤其是在拔牙后第7天。此外,与明胶海绵相比,使用速即纱治疗的患者疼痛评分显著更低,这反映了其在改善患者舒适度和加速愈合方面的作用。
本研究支持将速即纱作为服用抗凝剂患者控制出血和促进组织愈合的更有效选择,减少可能增加血栓形成风险的治疗调整需求。该研究建议进一步开展研究,以评估在该患者群体中使用不同止血剂的长期益处。
该试验于2025年5月29日在国际标准随机对照试验编号注册库(ISRCTN19155058)进行回顾性注册。